➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Medtronic
McKesson
Mallinckrodt
AstraZeneca

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Bavituximab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Bavituximab?

Bavituximab is an investigational drug.

There have been 26 clinical trials for Bavituximab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Peregrine Pharmaceuticals, University of Texas Southwestern Medical Center, and Merck Sharp & Dohme Corp.

There are thirty-six US patents protecting this investigational drug and eight hundred and forty-six international patents.

Recent Clinical Trials for Bavituximab
TitleSponsorPhase
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and NeckUniversity of Maryland, BaltimorePhase 2
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsMerck Sharp & Dohme Corp.Phase 2
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsOncologie Inc.Phase 2

See all Bavituximab clinical trials

Clinical Trial Summary for Bavituximab

Top disease conditions for Bavituximab
Top clinical trial sponsors for Bavituximab

See all Bavituximab clinical trials

US Patents for Bavituximab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bavituximab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Bavituximab   Start Trial .beta.-glucan methods and compositions that affect the tumor microenvironment BIOTHERA, INC. (Eagan, MN)   Start Trial
Bavituximab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Bavituximab   Start Trial Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Bavituximab   Start Trial Compositions and methods for detecting protease activity in biological systems CytomX Therapeutics, Inc. (South San Francisco, CA)   Start Trial
Bavituximab   Start Trial Methods and compositions for treating conditions associated with an abnormal inflammatory responses First Wave Bio, Inc. (Ann Arbor, MI)   Start Trial
Bavituximab   Start Trial Methods of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bavituximab

Drugname Country Document Number Estimated Expiration Related US Patent
Bavituximab Canada CA2900764 2033-02-08   Start Trial
Bavituximab European Patent Office EP2954056 2033-02-08   Start Trial
Bavituximab Hong Kong HK1218930 2033-02-08   Start Trial
Bavituximab Japan JP2016509014 2033-02-08   Start Trial
Bavituximab World Intellectual Property Organization (WIPO) WO2014124326 2033-02-08   Start Trial
Bavituximab China CN106687122 2034-07-10   Start Trial
Bavituximab China CN107106593 2034-07-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Medtronic
McKesson
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.